Document is current
Any future updates will be listed below
-
Authors
Schubl, Sebastian D.
Figueroa, Cesar
Palma, Anton M.
de Assis, Rafael R.
Jain, Aarti
Nakajima, Rie
Jasinskas, Algimantas
Brabender, Danielle
Hosseinian, Sina
Naaseh, Ariana
Hernandez Dominguez, Oscar
Runge, Ava
Skochko, Shannon
Chinn, Justine
Kelsey, Adam J.
Lai, Kieu T.
Zhao, Weian
Horvath, Peter
Tifrea, Delia
Grigorian, Areg
Gonzales, Abran
Adelsohn, Suzanne
Zaldivar, Frank
Edwards, Robert
Amin, Alpesh N.
Stamos, Michael J.
Barie, Philip S.
Felgner, Philip L.
Khan, Saahir
-
Funding
Funding for this research was provided by:
Office of the President, University of California (R00RG2646, R01RG3745, R00RG2646, R01RG3745, R00RG2646, R01RG3745)
School of Medicine, University of California, Irvine (COVID-19 Basic, Translational, and Clinical Research Fund, COVID-19 Basic, Translational, and Clinical Research Fund, COVID-19 Basic, Translational, and Clinical Research Fund)
Defense Advanced Research Projects Agency (N66001-17-2-4023, N66001-18-2-4015, N66001-17-2-4023, N66001-18-2-4015, N66001-17-2-4023, N66001-18-2-4015, N66001-17-2-4023, N66001-18-2-4015, N66001-17-2-4023, N66001-18-2-4015, N66001-17-2-4023, N66001-18-2-4015)
National Center for Advancing Translational Sciences (KL2 TR001416, UL1 TR001414, KL2 TR001416, UL1 TR001414, KL2 TR001416, UL1 TR001414)
National Cancer Institute (P30CA062203, P30CA062203, P30CA062203)
- License Information
-
More Information
Article History
Received: 4 May 2022
Accepted: 27 April 2023
First Online: 16 May 2023
Declarations
:
: The coronavirus antigen microarray is intellectual property of the Regents of the University of California that is licensed for commercialization to Nanommune Inc. (Irvine, CA), a private company for which P. Felgner is the largest shareholder and several co-authors (R. de Assis, A. Jain, R. Nakajima, and S. Khan) also own shares. Nanommune Inc. has a business partnership with Sino Biological Inc. (Beijing, China) which expressed and purified the antigens used in this study. A. Amin reports serving as a clinical trials investigator for NIH/NIAID, NeuroRx Pharma, Pulmotect, Blade Therapeutics, Novartis, Takeda, Humanigen, Eli-Lilly, PTC Therpeutics, OctaPharma, Fulcrum Therapeutics, and Alexion, and has served as a consultant and/or speaker for Bristol-Meyers-Squibb, Pfizer, Boehringer Ingelheim, Portola, Sunovion, Mylan, Salix, Alexion, Astra Zeneca, Novartis, Nabriva, Paratek, Bayer, Tetraphase, Achogen, LaJolla, Millenium, Aseptiscope, HeartRite, and Sprightly Health. S. Schubl, C. Figueroa, A. Palma, A. Jasinkas, D. Brabender, S. Hosseinian, A. Naaseh, O. Dominguez, A. Runge, S. Skochko, J. Chinn, A. Kelsey, K. Lai, W. Zhao, P. Horvath, D. Tifrea, A. Grigorian, A. Gonzales, S. Adelsohn, F. Zaldivar, R. Edwards, M. Stamos, and P. Barie have no competing interests. AA has been a principal investigator or co-investigator of clinical trials sponsored by NIH/NIAID, NeuroRx Pharma, Pulmotect, Blade Therapeutics, Novartis, Takeda, Humanigen, Eli Lilly, PTC Therapeutics, OctaPharma, Fulcrum Therapeutics, Alexion, Gilead and a speaker and/or consultant for BMS, Pfizer, BI, Portola, Sunovion, Mylan, Salix, Alexion, AstraZeneca, Novartis, Nabriva, Paratek, Bayer, Tetraphase, Achogen LaJolla, Ferring, Seres, Spero, Eli Lilly, Gilead, Millenium, HeartRite, Aseptiscope, and Sprightly; these relationships were unrelated to the current work.
: The study was approved by the Institutional Review Board of the University of California-Irvine under Protocol HS 2020–5818. All subjects were underwent electronic or written informed consent as outlined under IRB protocol HS 2020–5818. All methods and procedures were performed in accordance with the relevant guidelines and regulations.
: Not applicable.
